The ASA has prohibited a billboard advert for a £49 face serum after determining that claims it could make users look up to five years younger were deceptive and unproven. The poster for Eucerin Hyaluron-Filler Epigenetic Serum, which appeared at Balham tube station in London, claimed the product was “clinically proven” founded on a study of 160 people. However, the regulator identified major issues in the study design, such as the absence of a control group and reliance on subjective self-assessment from participants. The grievance was filed in November 2025, prompting the ASA investigation that ultimately deemed the advertisement deceptive and prohibited it from appearing in its current form.
The Restricted Campaign and Its Controversial Claims
The Eucerin advertisement relied heavily on a four-week study featuring 160 individuals who were simply asked to self-report how much more youthful they felt they appeared after using the serum. This methodology prompted immediate concerns for the ASA, which highlighted several critical weaknesses in the study design. Most notably, the study lacked a comparison group—a fundamental requirement in scientific studies that would have allowed researchers to compare results against a baseline. The absence of such comparisons meant there was no way to determine whether any apparent benefits were genuinely attributable to the serum or simply the result of placebo response, inherent skin differences, or additional outside influences.
Beiersdorf, the organisation behind Eucerin, attempted to defend the “up to five years younger” claim by contending it represented a real upper result rather than a common finding. However, the ASA’s concerns extended past the primary study. The watchdog highlighted that the serum had been assessed in a different geographical region to the United Kingdom, raising questions about whether results would translate to British consumers. Additionally, three supporting items of evidence presented by Beiersdorf consisted solely of unpublished research, whilst a fourth—a study that had been peer-reviewed on the main active component—did not even evaluate the serum itself, further undermining the substantiation for the ambitious anti-ageing assertions.
- Study was missing control group to verify genuine product performance
- Participant self-reporting created subjective bias into findings
- Testing conducted in different climate than UK conditions
- Supporting evidence mostly not published and questionable in methodology
Compliance Issues and Flawed Methodology
Why the Study Failed Standards
The ASA’s review revealed critical shortcomings in how Beiersdorf conducted and presented its research. The missing recruitment information meant the watchdog could not verify whether participants were genuinely representative of the broader consumer base or if sampling bias had skewed results towards favourable outcomes. Without knowing how volunteers were recruited, whether they had prior experience with skincare products, or if they held existing preferences for the brand, the credibility of their responses became deeply problematic. These methodological gaps are precisely the kind that watchdog organisations assess carefully when evaluating claims that could affect consumer choices.
Self-reporting by study participants introduced a significant layer of subjective bias into the findings. Asking individuals to gauge how many years younger they appeared is inherently unreliable, as perceptions of ageing are deeply personal and influenced by mental processes, lighting conditions, and individual expectations. The ASA rightly questioned whether participants’ responses represented actual physical alterations or merely their hopes and beliefs about the product’s efficacy. This distinction holds significant weight when a company seeks to market a £49 serum as “clinically proven”—a phrase implying rigorous, objective scientific validation rather than subjective personal impressions.
- No control group meant unable to determine the actual effects
- Selection methodology undisclosed, introducing selection bias concerns
- Subjective self-assessment cannot provide scientific evidence of efficacy
- Varying environmental conditions compromised applicability to UK consumers
- Backing data largely unpublished, restricting independent scientific scrutiny
Sector-Wide Problem with Beauty Advertising
The Eucerin serum ban is merely the latest in a pattern of false assertions that has plagued the cosmetics advertising industry for years. Beauty companies have consistently stretched the limits of permissible marketing language, leveraging aspirational messaging and pseudo-scientific language to persuade consumers that products provide transformative results. Lianne Sykes, an marketing specialist in aesthetics who consults with firms on ethical advertising practices, stresses that this issue is systemic rather than isolated. Companies often prioritise compelling marketing narratives over rigorous substantiation, relying on the presumption that consumers will not scrutinise claims too closely or that regulatory action will be slow.
The cosmetics sector benefits from inherent demand among consumers for visible improvements in appearance, creating fertile ground for exaggerated assertions. When companies use phrases like “clinically proven” without fulfilling the demanding criteria that such language demands, they exploit the trust customers put in scientific terminology. The ASA’s results suggest that Beiersdorf’s approach—offering unpublished research, running studies in inappropriate conditions, and relying on subjective self-assessment—constitutes a worrying but not uncommon strategy. Without consistent enforcement and greater transparency from manufacturers, consumers stay susceptible to marketing claims that emphasise profit over honesty.
What Consumers Should Question
Rather than adopting cosmetic claims at face value, consumers should establish a more discerning approach to evaluating cosmetic advertising. Sykes advises asking fundamental questions before purchasing, notably when companies make bold assertions about tangible results. Understanding the testing methods used, who participates in studies, and what measures are measured can uncover whether claims are grounded in solid evidence or promotional claims. Consumers must understand that healthy skin typically results from consistent habits and individual biology rather than dependence on a single miracle product, no matter its price point or branding.
- How is skin quality objectively measured and evaluated over time?
- Were studies performed on diverse age groups and skin types?
- Is the findings made public and objectively verifiable by researchers?
- Does the testing environment match actual conditions where consumers live?
Beiersdorf’s Reaction and Future Implications
Beiersdorf, the German multinational corporation behind the Eucerin brand, has maintained that its products are supported by legitimate scientific research carried out in line with industry standards. The company defended its choice to state the claim as “up to” five years younger, contending this phrasing correctly captured the genuine maximum result observed rather than a standard result. However, the ASA’s detailed scrutiny of the methodology—including the lack of a control group, absence of clarity about how participants were selected, and reliance on subjective self-reporting—suggests that sector guidelines by themselves may be insufficient to safeguard consumers from false claims.
The prohibition signals a wider movement in regulatory enforcement targeting cosmetics advertising, though uncertainty persists about whether isolated cases translate into systemic change. Beiersdorf stated that the billboard advertisement is no longer active in the United Kingdom, but the ruling highlights key concerns about how widely comparable assertions persist across other products and promotional platforms. If enforcement proceeds at this rate, companies may face increasing demands to commit resources to genuinely robust clinical evidence rather than relying on the vagueness surrounding unsubstantiated findings. For consumers, this case underscores the necessity of demanding transparency and questioning even well-established brands.